{"schema_version":"1","generated_at":"2026-11-20T12:21:43.255Z","data_as_of":null,"url":"https://www.findmykol.com/kol/paul-celano","json_url":"https://www.findmykol.com/kol/paul-celano/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"paul-celano","name":"Paul Celano","credential":"MD","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Greater Baltimore Medical Center","institution_url":"https://www.findmykol.com/institution/greater-baltimore-medical-center","city":"Baltimore","state":"MD","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"on_file":["npi","orcid","openalex"],"values":"Shown on the profile page to a signed-in account."},"summary":"Paul Celano is an Oncology physician affiliated with Greater Baltimore Medical Center. OpenAlex indexes 41 publications with 5,866 citations (h-index 23).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":41,"cited_by_count":5866,"h_index":23,"latest_activity_year":2026,"source":"works"},"payments":{"company_count":36,"program_years":{"first":2021,"last":null},"rows_total":64,"shown":3,"withheld":61,"rows":[{"payer":"Merck & Co.","program_year":2025,"amount_usd":26996.29,"payment_count":2},{"payer":"Pfizer","program_year":2025,"amount_usd":3000,"payment_count":1},{"payer":"SpringWorks Therapeutics","program_year":2025,"amount_usd":2390,"payment_count":12}],"source":"payments"},"prescribing":{"data_year":2023,"areas_total":10,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":68.5,"classes_total":8,"classes":[{"class":"Integrin Receptor Antagonist","setting":"administered","share_pct":37.6,"drugs":[{"name":"Vedolizumab","share_pct":100}],"max_beneficiaries":11},{"class":"PD-1 inhibitor","setting":"administered","share_pct":30.1,"drugs":[{"name":"Pembrolizumab","share_pct":100}],"max_beneficiaries":15}]},{"area":"Metabolism & gastrointestinal","share_pct":14,"classes_total":3,"classes":[{"class":"Other antiemetics","setting":"administered","share_pct":12.5,"drugs":[{"name":"Fosaprepitant","share_pct":100}],"max_beneficiaries":14},{"class":"Serotonin-3 Receptor Antagonist","setting":"administered","share_pct":1.4,"drugs":[{"name":"Palonosetron hcl","share_pct":100}],"max_beneficiaries":21}]},{"area":"Musculoskeletal","share_pct":13,"classes_total":2,"classes":[{"class":"RANK Ligand Inhibitor","setting":"administered","share_pct":12.2,"drugs":[{"name":"Denosumab","share_pct":100}],"max_beneficiaries":20},{"class":"Bisphosphonate","setting":"administered","share_pct":0.8,"drugs":[{"name":"Zoledronic acid","share_pct":100}],"max_beneficiaries":85}]}],"care_setting":{"dominant":"office","data_year":2023,"office_pct":100,"facility_pct":0},"source":"medicare"},"funding":{"award_count":1,"fiscal_years":{"first":1990,"last":1993},"rows_total":4,"shown":3,"withheld":1,"matched_by":"principal investigator name at an organization in the practice state","rows":[{"project":"R29CA051068","title":"REGULATION OF GROWTH GENE EXPRESSION BY THE POLYAMINES","fiscal_year":1993,"organization":"JOHNS HOPKINS UNIVERSITY","source_url":"https://reporter.nih.gov/quickSearch/R29CA051068"},{"project":"R29CA051068","title":"REGULATION OF GROWTH GENE EXPRESSION BY THE POLYAMINES","fiscal_year":1992,"organization":"JOHNS HOPKINS UNIVERSITY","source_url":"https://reporter.nih.gov/quickSearch/R29CA051068"},{"project":"R29CA051068","title":"REGULATION OF GROWTH GENE EXPRESSION BY THE POLYAMINES","fiscal_year":1991,"organization":"JOHNS HOPKINS UNIVERSITY","source_url":"https://reporter.nih.gov/quickSearch/R29CA051068"}],"source":"grants"},"publications":{"total":41,"shown":5,"withheld":36,"matched_by":"OpenAlex author record","recent":[{"title":"Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1","year":2026,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco-25-02693","status":"verified"},{"title":"Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1.4","year":2026,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco-26-01898","status":"verified"},{"title":"Phase II clinical trial of nirogacestat in patients with relapsed ovarian granulosa cell tumours","year":2026,"journal":"Clinical and Translational Medicine","source_url":"https://doi.org/10.1002/ctm2.70568","status":"verified"},{"title":"KANDLELIT-014: A phase 2 study of MK-1084 as monotherapy and in combination with cetuximab in KRAS G12C-mutant advanced solid tumors.","year":2026,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps3185","status":"verified"},{"title":"Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update","year":2025,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco-25-00007","status":"verified"}],"source":"works"},"similar":[{"name":"Susan Aucott","slug":"susan-aucott","institution":"Greater Baltimore Medical Center","specialty":"Pediatric Gastroenterology","url":"https://www.findmykol.com/kol/susan-aucott","json_url":"https://www.findmykol.com/kol/susan-aucott/profile.json"},{"name":"Janet Sunness","slug":"janet-sunness","institution":"Greater Baltimore Medical Center","specialty":"Ophthalmology","url":"https://www.findmykol.com/kol/janet-sunness","json_url":"https://www.findmykol.com/kol/janet-sunness/profile.json"},{"name":"Joan Blomquist","slug":"joan-blomquist","institution":"Greater Baltimore Medical Center","specialty":"Urogynecology and Reconstructive Pelvic Surgery","url":"https://www.findmykol.com/kol/joan-blomquist","json_url":"https://www.findmykol.com/kol/joan-blomquist/profile.json"},{"name":"William Crawley","slug":"william-crawley","institution":"Greater Baltimore Medical Center","specialty":"Plastic Surgery","url":"https://www.findmykol.com/kol/william-crawley","json_url":"https://www.findmykol.com/kol/william-crawley/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Stuart Orkin","slug":"stuart-orkin","institution":"Harvard Medical School","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/stuart-orkin","json_url":"https://www.findmykol.com/kol/stuart-orkin/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":61,"funding":1,"publications":36}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year"}},"methodology_url":"https://www.findmykol.com/about#methodology"}